COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,

NIH RePORTER · NIH · N01 · $2,229,415 · view on reporter.nih.gov ↗

Abstract

The objective of this contract program is to support improvements in the immunogenicity and durability of seasonal influenza vaccines, SARS-COV-2 vaccines and the development of innovative influenza vaccine approaches that provide robust, durable, broadly protective mucosal and systemic anti-influenza immunity (“universal influenza vaccines”) and other emerging or reemerging infectious diseases.

Key facts

NIH application ID: 10621132
Project number: 75N93019C00052-P00014-9999-2
Recipient: UNIVERSITY OF GEORGIA
Principal Investigator: TED ROSS
Activity code: N01
Funding institute: NIH
Fiscal year: 2022
Award amount: $2,229,415
Award type: —
Project period: 2019-09-10 → 2023-05-14